Écrit par Microfluidics | 20 Septembre 2011

Join Microfluidics and Quadro Engineering for a Webinar Presentation on Nano and Micron Sized Particle Production for the Nutraceuticals and Functional Foods Markets






Nano- and Micron- size formulations are used very often to create nutraceuticals and functional foods. Because the Nano- and Micron- sized particles are so small, they allow easier absorption of nutraceuticals by the...

Écrit par Pluristem Therapeutics | 12 Septembre 2011

Initial Animal Studies Suggest that PLX Cells Can Increase Survival Rates Following Exposure to Lethal Doses of Radiation

HAIFA, ISRAEL, September 7, 2011 -- Pluristem Therapeutics Inc. (NasdaqCM: PSTI; TASE: PLTR) announced today that animal studies it has conducted suggest that its PLacental eXpanded (PLX) cells are potentially effective in treating life threatening hematopoietic...

Écrit par Intersystems | 02 Septembre 2011

En renforçant ainsi sa présence sur le marché du SIH français, 5ème marché mondial, InterSystems apporte une offre encore plus complète et performante aux professionnels du secteur de la Santé.






Paris, le 1er Septembre 2011 - InterSystems Corporation a annoncé aujourd'hui l'acquisition stratégique de Siemens Health Services (SHS) France, une société du groupe Siemens. Leader...

Écrit par Pluristem Therapeutics | 01 Septembre 2011

HAIFA, ISRAEL, August 25, 2011 -- Pluristem Therapeutics, Inc. (NASDAQ:PSTI; TASE:PLTR) today announced that on August 22, 2011 the U.S. Food and Drug Administration (FDA) designated Pluristem’s PLX cells orphan status for the treatment of thromboangiitis obliterans (Buerger's disease). The Company also announced that a concurrent application in Europe at the EMA’s Committee for Orphan...